Get a Quote
Receive a tailored pricing based on your needs.
- Choose license type
- Multiple user options
- Custom scope & coverage
- Fast turnaround
"Designing Growth Strategies is in our DNA"
The global transcranial magnetic stimulation devices market size was valued at USD 327.6 million in 2025. The market is projected to grow from USD 367.9 million in 2026 to USD 846.3 million by 2034, exhibiting a CAGR of 11.0% during the forecast period.
Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technology in which a coil placed near the scalp generates rapidly changing magnetic fields. These fields induce electrical currents in targeted cortical regions and alter neuronal activity. The global market growth is driven primarily by the rising prevalence of mental health and neurological conditions globally.
Neuronetics, BrainsWay, Nexstim, MagVenture A/S, and Magstim held the highest market share in 2025 due to their strong product portfolio and strategic initiatives such as acquisitions, partnerships, collaborations, and others.
Shift Toward Multi-indication, Connected, and Navigation-enabled Platforms to Emerge as a Key Trend
Currently, TMS systems are becoming more flexible and capable of supporting multiple uses on a single platform due to advancements. Moreover, newly introduced systems combine treatment protocols with navigation, data tracking, different coil options, software-guided workflows, and diagnostic or research applications.
This shift is increasing demand for navigation, software, coils, and accessories, which are expected to expand more significantly than the core TMS stimulator systems.
Download Free sample to learn more about this report.
Expanding Depression Burden and Treatment Demand to Drive Market Growth
Over the past few years, there have been an increasing number of cases of depression worldwide. For instance, in September 2026, the World Health Organization (WHO) stated that around 322.0 million people experienced depression in 2023, representing about 5.2% of adults.
This large patient pool is contributing to the expansion of TMS clinics, new system installations, and higher treatment volumes. Moreover, demand is particularly driven by patients who do not respond well to medication, prefer non-drug treatment options, or have access to reimbursed TMS therapy. Such a scenario is anticipated to drive the market growth during the forecast period.
Market Drivers - Impact & CAGR Contribution (2026–2034)
| Rank | Market Drivers | Expected Impact on Market Growth | Estimated Gross Market Growth Contribution (USD Million) | Impact: 2026-2028 | Impact: 2029-2031 | Impact: 2032-2034 |
|---|---|---|---|---|---|---|
| 1 | Expanding depression burden and treatment demand | High | 180.0 | High | High | High |
| 2 | Expansion of reimbursement, payer coverage and TMS clinic access | High | 135.0 | High | High | High |
| 3 | Accelerated, theta-burst and higher-throughput treatment protocols | Medium-High | 110.0 | Medium | High | High |
| 4 | New indications, adolescent use and precision/navigation-enabled TMS | Medium-High | 85.0 | Medium | High | High |
| 5 | Emerging-market mental-health infrastructure and local manufacturing | Medium | 65.0 | Medium | Medium | Medium |
| 6 | Others (replacement cycles, leasing models, research demand, workflow software) | Low | 40.0 | Low | Low | Low |
| Total Gross Growth Contribution | 615 | |||||
Source: Fortune Business Insights
Download Free sample For In-Depth Market Restraints & Risk Analysis
High Equipment Costs and Uneven Reimbursement to Restrict Market Growth
Despite growing treatment demand, TMS adoption is limited by the high cost of equipment, treatment space, trained staff, and repeated patient visits. Additionally, reimbursement is available in some developed markets, but coverage varies by country. For instance, the World Health Organization (WHO) reported in 2025 that mental health receives only about 2.0% of global health budgets, while many countries also face shortages of mental-health professionals.
These funding and workforce gaps are expected to slow the adoption of TMS, particularly in lower-income and less-developed healthcare markets. Such a scenario is anticipated to hinder the market growth over the forecast period.
Market Restraints - Impact & Negative CAGR Contribution (2026–2034)
| Rank | Market Restraints | Expected Impact on Market Growth | Estimated Reduction in Market Size (USD Million) (2026-2034) |
Impact: 2026-2028 | Impact: 2029-2031 | Impact: 2032-2034 |
|---|---|---|---|---|---|---|
| 1 | High equipment costs and uneven reimbursement | High | 55.0 | High | High | Medium |
| 2 | Shortage of trained mental-health / TMS professionals and clinic capacity | Medium-High | 37.0 | High | Medium | Medium |
| 3 | Clinical-response variability and evidence/regulatory requirements for new indications | Medium | 29.0 | Medium | Medium | Medium |
| 4 | Others (competition from substitutes, price pressure, workflow and cybersecurity requirements) | Low | 15.6 | Low | Low | Low |
| Total Market Reduction | 136.6 | |||||
Source: Fortune Business Insights
Download Free sample For In-Depth Market Restraints & Risk Analysis
Accelerated and Precision TMS Workflows to Create Lucrative Opportunities
Accelerated and precision TMS protocols shorten treatment schedules and improve targeting accuracy. This makes treatment more convenient for patients while allowing clinics to treat more patients using the same equipment.
These advances are expected to create significant opportunities for higher clinic efficiency, greater system utilization, and wider adoption, especially where reimbursement supports newer treatment approaches. This is expected to fuel the market expansion in the near future.
Clinical Response Variability and Evidence Requirements to Challenge Market Expansion
Transcranial magnetic stimulation (TMS) devices do not work equally well for each patient, and treatment outcomes vary based on the condition, protocol, targeting method, and previous treatments.
Moreover, the focus of key players on expanding TMS into new indications and patient groups is driving the need for strong clinical evidence to support safety and effectiveness. This is expected to increase clinical trial costs, regulatory timelines, and commercialization risk. Henceforth, several emerging TMS applications remain limited to research until they receive regulatory approval and gain wider clinical adoption. This is anticipated to challenge the transcranial magnetic stimulation devices market growth during the forecast period.
Large Installed Base of TMS Stimulator Systems to Support Segment’s Growth
Based on product type, the market is segmented into TMS stimulator systems, TMS coils, navigation, mapping & positioning systems, TMS-specific accessories & consumables, and others.
The TMS stimulator systems segment accounted for the largest global transcranial magnetic stimulation devices market share in 2025 because it is the main capital equipment purchased by treatment centers. This leads to an overall higher installed based globally, contributing to the segment’s growth.
To know how our report can help streamline your business, Speak to Analyst
The TMS coils segment is projected to grow at an 11.7% CAGR during the forecast period.
Increasing Number of Depression Patients to Support Depressive Disorders Segment’s Growth
By application, the market is classified into depressive disorders, obsessive-compulsive disorder, addiction & substance-use disorders, neurological & pain management, cortical mapping & pre-surgical planning, and research & other applications.
The depressive disorders segment accounted for the largest market share in 2025. The segment’s growth is attributed to an increasing number of depression patients globally, which is an established indication for TMS devices. Moreover, the segment is set to acquire a 62.4% share in 2026.
The obsessive compulsive disorder segment is expected to grow at a CAGR of 12.5% during the forecast period.
Higher Capability to Treat Patients With TMS to Fuel the Hospitals & Health Systems Segment’s Growth
On the basis of end-user, the market is segmented into hospitals & health systems, independent psychiatric & TMS clinics, independent neurology & neurosurgery centers, universities & research institutes, and others.
In 2025, the hospitals & health systems segment dominated the market due to their higher capability of these settings to treat depression and OCD patients, which is expected to drive the demand for TMS devices. Furthermore, the segment is set to hold a 47.4% market share in 2026.
The independent psychiatric & TMS clinics segment is projected to grow at a CAGR of 11.7% during the forecast period.
Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America Transcranial Magnetic Stimulation Devices Market Size, 2025 (USD Million)
To get more information on the regional analysis of this market, Download Free sample
North America accounted for the largest share in 2024, valued at USD 134.9 million. It maintained its leading position in 2025, with USD 150.7 million, primarily due to the higher treatment rate of depression and product penetration in the U.S. and Canada. Additionally, favorable reimbursement coverage for eligible patients and the expansion of outpatient mental health treatment centers are contributing to the adoption of TMS devices across the region.
In 2026, the U.S. market is anticipated to reach USD 155.3 million, accounting for approximately 42.2% of the global sales.
Europe is projected to record a CAGR of 9.2% during the forecast period, the third-highest globally. The market is expected to reach USD 81.2 million in 2026. The region’s growth is attributed to the presence of key players and strong healthcare infrastructure supporting the adoption of Transcranial Magnetic Stimulation (TMS) devices.
The U.K. market is projected to reach USD 12.6 million in 2026, representing approximately 3.4% of global sales.
Germany's market is expected to reach USD 14.0 million in 2026, accounting for approximately 3.8% of global revenues.
In 2026, the market in Asia Pacific is projected to reach approximately USD 94.2 million, making it the second-largest market. The region’s growth is due to a large patient pool of neurological disorders in India, Japan, and China, which is expected to fuel the adoption of transcranial magnetic stimulation devices.
Japan’s market is projected to reach approximately USD 17.7 million in revenue in 2026, representing nearly 4.8% of the global sales.
In 2026, China’s market is anticipated to reach USD 36.2 million, accounting for approximately 9.9% of the global sales.
In 2026, India’s market is anticipated to reach USD 7.8 million, accounting for approximately 2.1% of the global sales.
Latin America and the Middle East & Africa are anticipated to witness moderate growth during the forecast period. The Latin America market is estimated to reach approximately USD 14.3 million in 2026. Latin America’s growth is supported by expanding private mental health services, which is offering significant opportunity for transmagnetic stimulation device adoption. Moreover, the market growth of the Middle East & Africa is mainly attributed to increasing healthcare infrastructure investment and key professionals, which is expected to influence key players to increase product penetration in this region.
In 2026, the GCC market is estimated to reach approximately USD 4.6 million, representing around 1.2% of global revenues.
Strong Brand Image, Investments, and Geographic Expansion Focus of Major Companies to Increase their Market Share
Neuronetics, BrainsWay, Nexstim, MagVenture A/S, and Magstim are prominent players in the global transcranial magnetic stimulation devices market. The dominance of these companies is attributed to their strong R&D investments, product launches, and brand image of the company in offering TMS systems.
Moreover, other prominent players are focusing on geographic expansion and strengthening distribution networks in emerging countries. This is expected to improve their market share in the forthcoming years.
The report offers detailed analysis of the global transcranial magnetic stimulation devices market across its key segments. It covers the major drivers, restraints, opportunities, challenges, and trends contributing to market growth. The study further examines the prevalence of depression, technological advancements, recent industry developments, competitive analysis, company market share analysis, and detailed profiles of major companies operating in the market.
Request for Customization to gain extensive market insights.
| ATTRIBUTE | DETAILS |
| Study Period | 2021-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2021-2024 |
| Growth Rate | CAGR of 11.0% from 2026-2034 |
| Unit | Value (USD Million) |
| Segmentation | By Product Type, Application, End-user, and Region |
| By Product Type |
|
| By Application |
|
| By End-user |
|
| By Region |
|
Fortune Business Insights says that the global market value stood at USD 327.6 million in 2025 and is projected to reach USD 846.3 million by 2034.
In 2025, the North America’s market value stood at USD 150.7 million.
The market is expected to exhibit a CAGR of 11.0% during the forecast period.
By product type, the TMS stimulator systems segment led the market.
The key factors driving the market are the expanding depression burden and treatment demand.
Neuronetics, BrainsWay, Nexstim, MagVenture A/S, and Magstim are the top players in the market.
North America dominated the market in 2025.
Get 30-60 hrs Free Customization
Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.
Related Reports
Get In Touch With Us
US +1 833 909 2966 ( Toll Free )
Receive a tailored pricing based on your needs.
Discuss your questions with our industry experts.
Have questions? Get quick answers before you purchase.